What is 340B Drug Pricing Program? Definition, Formula, and Benchmark

The 340B Drug Pricing Program, established under Section 340B of the Public Health Service Act (1992), requires pharmaceutical manufacturers participating in Medicaid to sell covered outpatient drugs at or below the 340B ceiling price to eligible safety-net providers known as "covered entities." The ceiling price is calculated from average manufacturer price (AMP) minus a unit rebate amount; typical 340B discounts range 20–50% below wholesale acquisition cost (WAC), with some drugs discounted more dramatically.

Covered entities include: Disproportionate Share Hospitals (DSH, with Medicaid-share thresholds), Children's Hospitals, Freestanding Cancer Hospitals, Rural Referral Centers and Sole Community Hospitals (with DSH thresholds), Critical Access Hospitals (no DSH threshold), Federally Qualified Health Centers (FQHCs) and FQHC Look-Alikes, Ryan White HIV/AIDS Program grantees, Native Hawaiian Health Centers, Tribal and Urban Indian Health Programs, Black Lung Clinics, Hemophilia Treatment Centers, Title X Family Planning Clinics, STD and TB Clinics, and Comprehensive Hemophilia Centers.

HRSA (Health Resources and Services Administration) oversees 340B administration. Covered entities must register, demonstrate continuing eligibility (revisited annually), and comply with statutory requirements: prevention of duplicate discounts (a manufacturer pays rebate to state Medicaid or provides 340B discount, not both for the same dispensation); prevention of diversion (only eligible patients can receive 340B-purchased drugs); meeting the statutory patient definition (Apexus/HRSA definition of patient includes established treatment relationship, patient care record, etc.).

For RCM, 340B economics are substantial for participating entities. A 340B-covered DSH hospital purchases expensive outpatient drugs (oncology, specialty pharmaceuticals, injectables) at significant discount below the Medicare reimbursement rate. The spread between 340B acquisition cost and Medicare reimbursement (often Medicare ASP +6% at the time of service) generates "340B margin" that supports uncompensated care, Medicaid care, and safety-net services. Major teaching hospitals and cancer centers generate tens to hundreds of millions of dollars in 340B margin annually.

340B claims billing requires careful tracking. Covered entities must distinguish 340B-purchased drugs from non-340B-purchased drugs; separate inventory and dispensing tracking typically managed through a 340B "split-billing" software. Medicare billing for 340B drugs uses the JG or TB modifier (JG: 340B-acquired drug for hospital outpatient, TB: 340B-acquired drug for hospital outpatient in rural settings and critical access hospitals). Medicaid billing uses state-specific modifiers (e.g., UD) to signal 340B purchases and prevent duplicate discount.

Contract pharmacy arrangements expand 340B reach. Covered entities without in-house pharmacies contract with retail pharmacies to dispense 340B drugs to eligible patients. HRSA's 2010 policy guidance permits multiple contract pharmacies; manufacturer challenges to contract-pharmacy policy have produced years of litigation and some manufacturer restrictions on 340B sales through contract pharmacies.

Compliance is complex and audit-intensive. HRSA conducts covered entity audits sampling drug purchase, dispensing, and patient eligibility data. Findings of diversion or duplicate discount require repayment and corrective action plans. Manufacturer audits ("manufacturer audits of covered entities") are allowed under statute but have been rare historically; recent manufacturer initiatives have challenged covered entity compliance more aggressively.

Policy debate around 340B is ongoing. Hospital advocacy groups (340B Health, America's Essential Hospitals) argue 340B is essential to safety-net mission. Manufacturer and drug-pricing critics argue 340B has grown beyond original intent without adequate program integrity. Legislation and CMS proposals periodically address 340B scope, transparency, and patient eligibility definitions.